Diffuse large B-cell lymphoma

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 35–40% of all cases of NHL. Despite high reported response rates to anthracycline-based combination chemotherapy regimens, only 50–65% of patients with this disease have achieved long-term disease-free survival with this approach. The emergence of new strategies, including monoclonal antibodies, dose-dense chemotherapy approaches and the identification of new rational therapeutic targets by gene expression profiling, has resulted in improvements in outcome for patients with this disease in recent years. Involvement of extranodal sites, either as a primary site of disease or as sites of dissemination, is relatively common in DLBCL. With the exception of primary central nervous system lymphoma (see Chapter 14) and some other specific anatomic sites, treatment recommendations for DLBCL are generally identical for nodal and extranodal disease, with the exception of single-site non-lower limb DLBCL of the skin (see Chapter 16). The clinical presentation of DLBCL, as with other types of NHL, is most commonly with painless lymphadenopathy. Approximately 25% of patients present with anatomically limited stage disease (clinical stage I or II), with the remaining 75% having more advanced disease (bulky stage II, or stage III–IV). Many patients will also experience constitutional (“B”) symptoms including drenching night sweats, unexplained fevers and unexplained weight loss of more than 10% of body weight. Since extranodal disease is relatively common in DLBCL, and since almost any organ can be affected by this disease, presenting symptoms may mimic many other diseases.

Original languageEnglish (US)
Title of host publicationLymphoma
Subtitle of host publicationPathology, Diagnosis and Treatment
PublisherCambridge University Press
Pages168-181
Number of pages14
ISBN (Electronic)9780511663369
ISBN (Print)9780521865449
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Non-Hodgkin's Lymphoma
Sweat
Anthracyclines
Gene Expression Profiling
Combination Drug Therapy
Disease-Free Survival
Weight Loss
Lymphoma
Fever
Extremities
Central Nervous System
Monoclonal Antibodies
Body Weight
Drug Therapy
Skin
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sweetenham, J. W. (2007). Diffuse large B-cell lymphoma. In Lymphoma: Pathology, Diagnosis and Treatment (pp. 168-181). Cambridge University Press. https://doi.org/10.1017/CBO9780511663369.013

Diffuse large B-cell lymphoma. / Sweetenham, John W.

Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press, 2007. p. 168-181.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sweetenham, JW 2007, Diffuse large B-cell lymphoma. in Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press, pp. 168-181. https://doi.org/10.1017/CBO9780511663369.013
Sweetenham JW. Diffuse large B-cell lymphoma. In Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press. 2007. p. 168-181 https://doi.org/10.1017/CBO9780511663369.013
Sweetenham, John W. / Diffuse large B-cell lymphoma. Lymphoma: Pathology, Diagnosis and Treatment. Cambridge University Press, 2007. pp. 168-181
@inbook{e5ac6ebde14c45b9aecb18a047743874,
title = "Diffuse large B-cell lymphoma",
abstract = "Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 35–40{\%} of all cases of NHL. Despite high reported response rates to anthracycline-based combination chemotherapy regimens, only 50–65{\%} of patients with this disease have achieved long-term disease-free survival with this approach. The emergence of new strategies, including monoclonal antibodies, dose-dense chemotherapy approaches and the identification of new rational therapeutic targets by gene expression profiling, has resulted in improvements in outcome for patients with this disease in recent years. Involvement of extranodal sites, either as a primary site of disease or as sites of dissemination, is relatively common in DLBCL. With the exception of primary central nervous system lymphoma (see Chapter 14) and some other specific anatomic sites, treatment recommendations for DLBCL are generally identical for nodal and extranodal disease, with the exception of single-site non-lower limb DLBCL of the skin (see Chapter 16). The clinical presentation of DLBCL, as with other types of NHL, is most commonly with painless lymphadenopathy. Approximately 25{\%} of patients present with anatomically limited stage disease (clinical stage I or II), with the remaining 75{\%} having more advanced disease (bulky stage II, or stage III–IV). Many patients will also experience constitutional (“B”) symptoms including drenching night sweats, unexplained fevers and unexplained weight loss of more than 10{\%} of body weight. Since extranodal disease is relatively common in DLBCL, and since almost any organ can be affected by this disease, presenting symptoms may mimic many other diseases.",
author = "Sweetenham, {John W.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1017/CBO9780511663369.013",
language = "English (US)",
isbn = "9780521865449",
pages = "168--181",
booktitle = "Lymphoma",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Diffuse large B-cell lymphoma

AU - Sweetenham, John W.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 35–40% of all cases of NHL. Despite high reported response rates to anthracycline-based combination chemotherapy regimens, only 50–65% of patients with this disease have achieved long-term disease-free survival with this approach. The emergence of new strategies, including monoclonal antibodies, dose-dense chemotherapy approaches and the identification of new rational therapeutic targets by gene expression profiling, has resulted in improvements in outcome for patients with this disease in recent years. Involvement of extranodal sites, either as a primary site of disease or as sites of dissemination, is relatively common in DLBCL. With the exception of primary central nervous system lymphoma (see Chapter 14) and some other specific anatomic sites, treatment recommendations for DLBCL are generally identical for nodal and extranodal disease, with the exception of single-site non-lower limb DLBCL of the skin (see Chapter 16). The clinical presentation of DLBCL, as with other types of NHL, is most commonly with painless lymphadenopathy. Approximately 25% of patients present with anatomically limited stage disease (clinical stage I or II), with the remaining 75% having more advanced disease (bulky stage II, or stage III–IV). Many patients will also experience constitutional (“B”) symptoms including drenching night sweats, unexplained fevers and unexplained weight loss of more than 10% of body weight. Since extranodal disease is relatively common in DLBCL, and since almost any organ can be affected by this disease, presenting symptoms may mimic many other diseases.

AB - Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 35–40% of all cases of NHL. Despite high reported response rates to anthracycline-based combination chemotherapy regimens, only 50–65% of patients with this disease have achieved long-term disease-free survival with this approach. The emergence of new strategies, including monoclonal antibodies, dose-dense chemotherapy approaches and the identification of new rational therapeutic targets by gene expression profiling, has resulted in improvements in outcome for patients with this disease in recent years. Involvement of extranodal sites, either as a primary site of disease or as sites of dissemination, is relatively common in DLBCL. With the exception of primary central nervous system lymphoma (see Chapter 14) and some other specific anatomic sites, treatment recommendations for DLBCL are generally identical for nodal and extranodal disease, with the exception of single-site non-lower limb DLBCL of the skin (see Chapter 16). The clinical presentation of DLBCL, as with other types of NHL, is most commonly with painless lymphadenopathy. Approximately 25% of patients present with anatomically limited stage disease (clinical stage I or II), with the remaining 75% having more advanced disease (bulky stage II, or stage III–IV). Many patients will also experience constitutional (“B”) symptoms including drenching night sweats, unexplained fevers and unexplained weight loss of more than 10% of body weight. Since extranodal disease is relatively common in DLBCL, and since almost any organ can be affected by this disease, presenting symptoms may mimic many other diseases.

UR - http://www.scopus.com/inward/record.url?scp=84872426872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872426872&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511663369.013

DO - 10.1017/CBO9780511663369.013

M3 - Chapter

AN - SCOPUS:84872426872

SN - 9780521865449

SP - 168

EP - 181

BT - Lymphoma

PB - Cambridge University Press

ER -